SCHEMBL24252954

SCHEMBL24252954

SC(S)(S)Oc1ccc(Cl)cc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
SMN1; SMN2 Q16637 6/20 0.40
NPC1 O15118 3/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 4/20 0.39
ALDH1A1 P00352 6/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
PPARA Q07869 1/20 0.38
GAA P10253 1/20 0.38
EPAS1 Q99814 2/20 0.37
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
KDM4E B2RXH2 2/20 0.36
SLC6A3 Q01959 1/20 0.36
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10872384 0.80 L3MBTL1 (0.49) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL30467694 0.77 L3MBTL1 (0.47) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL24253085 0.77 L3MBTL1 (0.47) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL24252932 0.77 L3MBTL1 (0.47) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL30452866 0.77 L3MBTL1 (0.47) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL24252446 0.76 L3MBTL1 (0.46) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL30467695 0.76 L3MBTL1 (0.46) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL30467654 0.74 L3MBTL1 (0.44) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL929274 0.72 ALDH1A1 (0.52) L3MBTL1SMN1; SMN2NPC1MAPTMEN1
SCHEMBL29958505 0.72 ALDH1A1 (0.52) L3MBTL1SMN1; SMN2NPC1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.